help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bale, L. K.
Right arrow Articles by Conover, C. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bale, L. K.
Right arrow Articles by Conover, C. A.

Endocrinology, Vol 131, 608-614, Copyright © 1992 by Endocrine Society


ARTICLES

Regulation of insulin-like growth factor binding protein-3 messenger ribonucleic acid expression by insulin-like growth factor I

LK Bale and CA Conover
Endocrine Research Unit, Mayo Clinic, Rochester, Minnesota 55905.

Insulin-like growth factor binding protein-3 (IGFBP-3) is an important modulator of the anabolic and mitogenic actions of the insulin-like growth factor (IGF) peptides. Previous studies have shown that the IGFs themselves can elevate levels of IGFBP-3 in vivo and in vitro. However, the regulatory mechanisms responsible for IGF-induced increases in IGFBP-3 are unclear. In this study we examined the expression of messenger RNA (mRNA) encoding IGFBP-3 in cultured bovine and human fibroblasts, two cell lines that secrete IGFBP-3 under IGF-I control. Northern analysis of bovine fibroblast RNA hybridized with a specific bovine IGFBP-3 complementary DNA probe indicated a single 2.8-kilobase (kb) transcript readily detectable within 2 h in IGF-I- or insulin- treated, but not in untreated, cells. IGFBP-3 mRNA abundance was maximal around 6 h, and remained elevated after 24 h of treatment. Secreted IGFBP-3 protein appeared more slowly. By Western ligand blotting, IGFBP-3 was not detected in medium from bovine fibroblasts incubated with IGF-I for 2, 4, or 6h, but was apparent after 24 h IGF-I treatment. Induction of IGFBP-3 mRNA was blocked when RNA synthesis was inhibited by actinomycin D. Furthermore, IGFBP-3 mRNA and protein was induced by different IGF-I analogs in direct relation to the ability of the peptides to bind to the type I IGF receptor, indicating a receptor- mediated process. GH had no effect on IGFBP-3 mRNA or protein levels in these cells. In contrast to its effect in bovine fibroblasts, IGF-I had no significant effect on steady state levels of IGFBP-3 mRNA in cultured human fibroblasts. A human IGFBP-3 complementary DNA probe hybridized to a single 2.8-kilobase mRNA species abundant in normal and SV40-transformed human fibroblasts under all culture conditions, and IGFBP-3 protein was secreted by these cells in the absence of exogenous stimuli. In human fibroblast cultures, IGF-I rapidly increased levels of IGFBP-3 in the medium without influencing transcript levels. Steady state levels of induced or constitutively expressed IGFBP-3 mRNA did not change significantly after 6h in the presence of actinomycin D, even though general RNA synthesis was inhibited more than 98%. These data demonstrate that expression of mRNA encoding IGFBP-3 is differentially controlled by IGF-I in bovine and human fibroblasts. Whereas cultured human fibroblasts may be suitable to study posttranscriptional regulation of IGFBP-3 availability, cultured bovine fibroblasts may provide a useful model system to probe the molecular mechanisms of IGFBP-3 gene expression and regulation by IGF-I.


This article has been cited by other articles:


Home page
EndocrinologyHome page
J. Paquette, B. Bessette, E. Ledru, and C. Deal
Identification of Upstream Stimulatory Factor Binding Sites in the Human IGFBP3 Promoter and Potential Implication of Adjacent Single-Nucleotide Polymorphisms and Responsiveness to Insulin
Endocrinology, December 1, 2007; 148(12): 6007 - 6018.
[Abstract] [Full Text] [PDF]


Home page
Endocr. Rev.Home page
A. A. Samani, S. Yakar, D. LeRoith, and P. Brodt
The Role of the IGF System in Cancer Growth and Metastasis: Overview and Recent Insights
Endocr. Rev., February 1, 2007; 28(1): 20 - 47.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
U. Sivaprasad, J. Fleming, P. S. Verma, K. A. Hogan, G. Desury, and W. S. Cohick
Stimulation of Insulin-Like Growth Factor (IGF) Binding Protein-3 Synthesis by IGF-I and Transforming Growth Factor-{alpha} Is Mediated by Both Phosphatidylinositol-3 Kinase and Mitogen-Activated Protein Kinase Pathways in Mammary Epithelial Cells
Endocrinology, September 1, 2004; 145(9): 4213 - 4221.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
J. M. Pell, R. A. Hill, C. E. H. Stewart, C. R. Weston, and H. C. Flick-Smith
Enhancement of Insulin-Like Growth Factor I Activity by Novel Antisera: Potential Structure/Function Interactions
Endocrinology, February 1, 2000; 141(2): 741 - 751.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
T. Thomas, F. Gori, T. C. Spelsberg, S. Khosla, B. L. Riggs, and C. A. Conover
Response of Bipotential Human Marrow Stromal Cells to Insulin-Like Growth Factors: Effect on Binding Protein Production, Proliferation, and Commitment to Osteoblasts and Adipocytes
Endocrinology, November 1, 1999; 140(11): 5036 - 5044.
[Abstract] [Full Text]


Home page
J. Clin. Endocrinol. Metab.Home page
M. E. Wilson
Effects of Estradiol and Exogenous Insulin-Like Growth Factor I (IGF-I) on the IGF-I Axis during Growth Hormone Inhibition and Antagonism
J. Clin. Endocrinol. Metab., November 1, 1998; 83(11): 4013 - 4021.
[Abstract] [Full Text]


Home page
J. Biol. Chem.Home page
T. C. Haddad and C. A. Conover
Insulin and Interleukin-4 Induce Desensitization to the Mitogenic Effects of Insulin-like Growth Factor-I. PIVOTAL ROLE FOR INSULIN RECEPTOR SUBSTRATE-2
J. Biol. Chem., August 1, 1997; 272(31): 19525 - 19531.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
J. S. Freeth, R. M. Ayling, A. J. Whatmore, P. Towner, D. A. Price, M. R. Norman, and P. E. Clayton
Human Skin Fibroblasts as a Model of Growth Hormone (GH) Action in GH Receptor-Positive Laron's Syndrome
Endocrinology, January 1, 1997; 138(1): 55 - 61.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
C. A. Conover, S. K. Durham, Jür. Zapf, F. R. Masiarz, and M. C. Kiefer
Cleavage Analysis of Insulin-like Growth Factor (IGF)-dependent IGF-binding Protein-4 Proteolysis and Expression of Protease-resistant IGF-binding Protein-4 Mutants
J. Biol. Chem., March 3, 1995; 270(9): 4395 - 4400.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1992 by The Endocrine Society